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Background: Progressive hepatic fibrosis (HF) is a prominent feature of biliary atresia (BA), 
the most common indication for liver transplantation (LT) in children. Despite its importance in 
BA, HF is not evaluated in routine patient care because the invasiveness of liver biopsy makes 
histologic monitoring of fibrosis unfeasible. Therefore, the identification of noninvasive markers 
to assess HF is desirable especially in children.
Purpose: The main goal of this pilot project was to establish an investigational framework 
correlating hepatic expression of fibrogenic markers with routine blood tests in BA.
Methods: Using liver explants from patients with BA (n = 26), immune-expression of connec-
tive tissue growth factor (CTGF), a key fibrogenic cytokine was determined using horseradish-
labeled antibodies. Expression intensities of lobular (L-CTGF) and portal (P-CTGF) CTGF 
were determined by using ImageJ software. These CTGF intensities were correlated with blood 
tests performed at the time of LT. Correlation coefficients were determined for each blood test 
variable versus mean L-CTGF and P-CTGF expression intensities. A P-value of less than 0.05 
was considered statistically significant.
Results: All patients had end-stage liver disease and persistent cholestasis at the time of  LT. Kendall 
tau (τ) rank correlation coefficient for L-CTGF and white blood cell (WBC) was inversed (-0.52; 
P # 0.02). Similar but statistically nonsignificant inverse relationships were noted between L-CTGF 
and prothrombin time (PT) (-0.15; P # 0.4), international normalized ratio (INR) (-0.14; P # 0.5), 
and platelet count (-0.36; P # 0.09). Inversed (τ) rank correlation coefficients were also evident 
between P-CTGF expression and gamma-glutamyl transpeptidase (GGT), PT, INR, and platelet 
count. Pearson correlation coefficients for combinational analysis of standardized total bilirubin 
(TB), alkaline phosphatase, GGT, and platelet count with L-CTGF (0.33; P = 0.3) and P-CTGF 
(0.06; P = 0.8), were not significant. Similar analysis for alanine aminotransferase, TB, and GGT 
combination (L-CTGF, 0.16; P = 0.5; P-CTGF -0.3; P = 0.2) as well as WBC, platelet count, and 
TB (L-CTGF: -0.36; P = 0.09; P-CTGF -0.33; P = 0.13) also revealed nonsignificant results.
Conclusion: Hepatic expression of fibrogenic markers can be correlated with routinely 
  performed blood tests in patients with BA. We document that although a trend of inverse rela-
tionship is noted, hepatic CTGF expression does not correlate well with routinely performed 
blood tests in advanced BA. Further work is required to determine more reliable ways of 
noninvasive diagnosis of HF.
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Introduction
Progressive hepatic fibrosis (HF) is a hallmark feature of biliary atresia (BA), the 
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pathogenesis of BA remains elusive, it is generally agreed 
that the BA-phenotype can result from diverse mechanisms 
of liver injury, provoking a stereotypic response comprised 
of inflammation, bile duct proliferation, apoptosis, and 
  fibrogenesis.1 In this context, it is not surprising that HF is 
the most important predictor of the success of palliative Kasai 
porto-enterostomy (PE) surgery.2–4 However, assessment of 
HF has not yet been incorporated into routine post-PE patient 
care, mostly due to a lack of reliable noninvasive markers 
for assessing liver fibrosis. For the same reasons, even with 
advanced cirrhosis due to BA, the prognostic models utilized 
for listing patients for LT incorporate clinical and biochemi-
cal variables not related to the process of liver fibrosis.5,6 
As such, identification and validation of noninvasive tools 
for assessing liver fibrosis can have a major favorable impact 
on post-PE patient care, especially desirable to overcome the 
drawbacks of liver biopsy.7,8 Although several putative sero-
logic markers of fibrosis have been studied in adults such as 
hepatic aminotransferases and coagulation profiles, these tests 
can only partially reflect the extent of hepatic   dysfunction, 
and they fail to reflect the balance between extracellular 
matrix (ECM) production and resolution. Similarly, assays 
of markers of ECM synthesis and degradation, despite their 
mechanistic appeal, only provide a cross-sectional glimpse 
of otherwise dynamic fibrogenic processes.
Connective tissue growth factor (CTGF), a 349-residue 
cysteine-rich protein first described as a secretory product 
of the vascular endothelial cell,9 is now the focus of intense 
research as a master fibrogenic cytokine involved in liver 
fibrosis due to a variety of liver diseases10–12 and other 
organs.13–23 Although only limited information is available 
in the literature about hepatic CTGF-expression in BA,24,25 
it has been documented that not only that serum levels of 
CTGF were higher in patients with BA, but that these levels 
also correlated with worsening liver function.26 Liver fibrosis 
was not assessed in this study, thus leaving the question: can 
serum CTGF level be utilized as a marker of severity of HF 
in this disease? To answer this question, related and perhaps 
more fundamental questions requiring elaboration include: 
can hepatic-CTGF-expression be quantified at different 
stages of fibrosis, and if so, can the hepatic   CTGF-expression 
(portal [P-CTGF] and lobular [L-CTGF]) be correlated 
with routinely performed blood tests? To address these 
questions and to establish a framework for the evalua-
tion of CTGF as a biomarker of HF, our goal in this study 
was to determine whether routinely performed blood tests 
  correlate with hepatic-CTGF-expression in advanced BA. 
To accomplish this goal, CTGF expression was determined 
by   immunohistochemistry on the liver explant specimens 
obtained from children requiring LT for BA. The intensity 
of CTGF expression was then correlated with blood tests 
performed at the time of LT.
Materials and methods
Ethical considerations and access  
to human liver tissues and blood results
After approval from the Institutional Review Board of the 
University of Florida (UF), BA patients requiring liver 
transplantation between 2000 and 2008 were identified 
from the UF liver transplant database (n = 26, 14 male, 
12 female). The mean age at the time of liver transplanta-
tion was 1.8 ± 0.369 years (range, 2 months to 17 years). 
Blood levels of aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), alkaline phosphatase (ALP), total 
bilirubin (TB), albumin, total protein (TP), prothrombin 
time (PT), international normalized ratio (INR), white 
blood cell (WBC) count, and platelet counts performed 
at the time of LT were recorded. Archived liver sections 
of living-related-liver-donors were used as controls. All 
biopsies were 4 µm thick, fixed in phosphate-buffered for-
malin, and embedded in paraffin. At a randomly selected 
site of the explant, serial adjacent sections were used for 
hematoxylin and eosin staining immunohistochemistry, 
and trichrome staining. As we have recently reported,27 the 
stage of liver fibrosis was determined in a blinded fashion by 
using trichrome-stained slides according to the METAVIR 
scoring system.
CTGF immunohistochemistry
After rehydration, 4 µm sections of paraffin-embedded tissue 
on glass slides were incubated in 3% hydrogen peroxide to 
block the endogenous peroxidase activity followed by incu-
bation in 3% bovine serum albumin in phosphate buffered 
saline (PBS). A polyclonal CTGF antibody (Abcam ab6992) 
was applied at 1:1000, diluted in 3% bovine serum albumin 
and incubated at 4°C overnight. This antibody has been 
extensively used for immune localization of CTGF in variety 
of tissues.28–30 After being washed for 5 minutes in PBS, the 
slides were treated with goat anti-rabbit IgG horseradish 
peroxidase-labeled secondary antibodies (KPL, 474-1516) 
at a dilution of 2:500 for 30 minutes at room temperature. 
Bound antibodies were detected with an avidin-biotin com-
plex (ABC) kit (Vector Laboratories, Burlingame, CA). 
The slides were stained with diaminobenzidine, washed, 
counterstained with Mayer’s hematoxylin, dehydrated, 
treated with xylene, and mounted.Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
51
Hepatic CTGF expression and blood tests in biliary atresia
Determination of intensity of L-CTGF 
and P-CTGF expression
The intensities of the L-CTGF and P-CTGF were determined 
using ImageJ software (http://rsb.info.nih.gov/ij). From each 
slide, five random portal and lobular areas were analyzed 
with a color histogram and a color deconvolution plug-in 
routinely used for diaminobenzidine staining.31
Data analysis
Our hypothesis was that the relationship between hepatic 
expression of CTGF and the routinely performed blood tests 
can be established. To test the hypothesis, correlation coef-
ficients were calculated using SAS software (SAS Institute, 
Inc, Cary, NC). The response variables selected for the analy-
sis were the mean intensities of L-CTGF and P-CTGF. The 
dependent variables included in this analysis were AST, ALT, 
ALP, gamma-glutamyl transpeptidase (GGT), TB, direct bili-
rubin (DB), TP, albumin, PT, INR, hemoglobin, hematocrit, 
WBC, and the platelet count. These variables were selected 
to represent cholestasis, a prominent feature of advanced 
BA, and the common complications of BA including portal 
hypertension and chronic liver failure. For the corelational 
analysis, Kendall’s tau correlation coefficients were deter-
mined for each dependent variable versus mean L-CTGF 
and P-CTGF expression intensities. A P-value of less than 
0.05 was considered statistically significant. In addition, by 
way of principal component method, the coefficients for the 
linear combinations of standardized dependent variables 
were calculated. These combinations were determined 
to reflect typical pathophysiologic manifestations of BA. 
For example, to assess the effect of the degree of cholestasis 
and portal hypertension, a linear-combination of TB, ALP, 
GGT, and platelet count were used to determine the Pearson 
correlation coefficient for L-CTGF and P-CTGF. Similar 
combinational analysis for ALT, TB, and GGT as well as 
WBC, platelet count, and TB were calculated. Because 
children with advanced BA frequently receive exogenous 
albumin and vitamin K supplements, to avoid a confounding 
effect, albumen and INR were not incorporated in any of the 
combinational analyses.
Results
All of the explant liver specimens exhibited advanced biliary 
cirrhosis, a typical sequel of BA requiring LT. Clinically, all 
patients had end-stage liver disease and persistent cholesta-
sis (mean TB of 14 mg/dL) at the time of LT. A summary 
of analysis of each of the dependent variables is provided 
in Table 1. Kendall’s tau correlation coefficients for each 
dependent variable and the mean P-CTGF is shown in 
Table 2, whereas Table 3 outlines the correlation coefficients 
for each dependent variable and mean L-CTGF. As seen in 
Table 2, GGT, PT, INR, and platelet count had an inverse 
relationship with P-CTGF expression. In contrast, all other 
variables had a positive correlation with P-CTGF. However, 
as noted in the tables, it is important to recognize that most 
of the positive and reciprocal relationships are not statisti-
cally significant. Interestingly, as compared with P-CTGF, 
stronger inverse relationships were noted in the corelational 
analysis of L-CTGF. For example, as seen in Table 3, the 
correlation coefficient for L-CTGF and WBC was inversed 
Table 1 summary of dependent variables at the time of liver transplantation
Variable Mean ± SEM Median Minimum Maximum
AsT (U/L) 264 ± 39 211 67 960
ALT (U/L) 181 ± 35 139 39 894
ALP (U/L) 647 ± 65 665 81 1513
GGT (U/L) 282 ± 61 209 15 825
TB (mg/dL) 14 ± 1.8 13 1.4 34
Direct bilirubin (mg/dL) 9 ± 2 7.6 0.1 23
Total protein (mg/dL) 5.8 ± 0.2 5.8 2.2 7.3
Albumin (mg/dL) 2.9 ± 0.1 3.1 1 3.9
Prothrombin time (seconds) 16.8 ± 0.5 16.7 12.7 24.5
international normalized ratio 1.5 ± 0.05 1.5 1.1 2.2
Hemoglobin (g/dL) 10 ± 0.3 10.2 7.2 12.9
Hematocrit (29.0%–41.0%) 31 ± 0.8 31.5 22.7 40
WBC (6.0–17.5) × 109/L 11 ± 0.9 1.3 1.7 20.5
Platelets (150–450) × 109/L 219 ± 28 214 54 780
Notes: results of the blood tests performed (Variable column) at the time of liver transplantation were retrieved from University of Florida transplant database. GraphPad 
was used to generate the summary of descriptive statistics.
Abbreviations: AsT, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; GGT, gamma-glutamyltransferase; sEM, standard error of the 
mean; TB, total bilirubin; WBC, white blood cell count.Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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(-0.52; P # 0.02). Similar inverse relationships were noted 
between L-CTGF and PT, INR, and platelet count (-0.36; 
P # 0.09). Pearson correlation coefficients for combina-
tional analysis of standardized TB, ALP, GGT, and platelet 
with L-CTGF (0.33; P = 0.3) and P-CTGF (0.06; P = 0.8), 
were not significant. Similar analysis for ALT, TB, and GGT 
combination (L-CTGF, 0.16; P = 0.5; P-CTGF -0.3; P = 0.2) 
as well as WBC, platelet count, and TB (L-CTGF: -0.36; 
P = 0.09; P-CTGF -0.33; P = 0.13) also revealed nonsignifi-
cant results. In summary, hepatic CTGF expression is noted 
to have an inverse albeit nonsignificant relationship with 
routinely performed hematological parameters. This is best 
depicted by L-CTGF expression and poorly by the P-CTGF 
expression. Both L-CTGF and P-CTGF had poor correlation 
with combinational analysis of dependent variables.
Discussion
Identification and validation of novel noninvasive surrogate 
markers of liver fibrosis has been slow due to poor elucidation 
of the mechanisms of fibrogenesis. This is especially true in 
pediatric cholestatic liver disorders such as BA, in which, a 
systematic approach to understanding the mechanisms of 
liver fibrogenesis has been lacking. Similarly, even in chronic 
liver disease affecting adults, various noninvasive methods to 
quantify liver fibrosis are still in the process of evaluation and 
no marker, individually or as a composite index has replaced 
liver biopsy. For example, a systematic review of 14 studies 
of fibrosis biomarkers in patients with chronic hepatitis C 
(HCV) concluded that the panels of biomarkers could not 
differentiate stages of fibrosis   accurately.32 Therefore, any 
putative biomarker of fibrosis such as CTGF requires careful 
investigations in a variety of liver diseases to determine its 
potential use as a biomarker of liver   fibrosis. An ideal nonin-
vasive fibrosis biomarker must be: liver   specific; independent 
of metabolic alterations in liver, renal, or reticuloendothelial 
function; easy to perform; minimally altered by urinary or 
biliary excretion; reflective of fibrosis in all types of chronic 
liver injury; sensitive enough to discriminate between differ-
ent stages of fibrosis; able to correlate dynamic changes in 
fibrosis progression or regression; and able to predict clinical 
outcomes, including liver failure and mortality. The discovery 
of novel biomarkers fulfilling all of these criteria is a chal-
lenge that will require concurrent understanding of the cellular 
process and the molecular mechanisms involved in hepatic 
fibrogenesis. At present, no single or panel marker fulfills all 
of these criteria sufficiently to merit routine clinical use.
In this pilot project, we document that the relationship 
between hepatic CTGF and routinely performed blood tests 
can be established by quantitative assessment of immune-
based CTGF expression. Pertinent observations of our 
study include the following: 1) L-CTGF is better   correlated 
Table  2  Correlational  analysis  of  routinely  performed  blood 
tests (dependent variables) and P-CTGF expression
Variable Kendall tau (τ) rank  
correlation coefficient  
(P-CTGF)
P-value
AsT 0.48 0.0282
ALT 0.36 0.0998
ALP 0.06 0.7839
GGT -0.33 0.1797
Total bilirubin 0.31 0.1682
Direct bilirubin 0.29 0.1916
Total protein 0.02 0.9452
Albumin 0 1.0000
Prothrombin time  -0.15 0.4908
international normalized ratio -0.11 0.6243
Hemoglobin 0.11 0.6304
Hematocrit 0.22 0.3348
WBC  -0.18 0.4106
Platelets  -0.33 0.1314
Notes: Hepatic CTGF expression in BA was determined by immunostaining of 
liver-explants (n = 26) by using commercially available primary antibodies. Means 
of color pixel histograms representing the intensities of P-CTGF expression was 
determined by imageJ software. Kendall tau (τ) rank correlation coefficients (middle 
column) were then determined for the mean intensities of P-CTGF and blood tests 
performed at the time of LT (left-hand column).
Abbreviations: AsT, aspartate aminotransferase; ALT, alanine aminotransferase; 
ALP,  alkaline  phosphatase;  BA,  biliary  atresia;  CTGF,  connective  tissue  growth 
factor; GGT, gamma-glutamyltransferase; LT, liver transplantation; P-CTGF, portal 
CTGF; WBC, white blood cell count.
Table 3 Correlational analysis of dependent variables and L-CTGF 
expression
Dependent  
variable
Correlation coefficient  
(L-CTGF)
P-value
AsT  0.09 0.6
ALT  0.21 0.3
ALP  0.09 0.6
GGT  0.11 0.6
Total bilirubin  0.03 0.8
Direct bilirubin  0.05 0.8
Total protein 0.29 0.1
Albumin  0.13 0.5
Prothrombin time  -0.15 0.4
international normalized ratio -0.14 0.5
Hemoglobin  0.38 0.08
Hematocrit  0.52 0.02
WBC  -0.52 0.02
Platelets  -0.36 0.09
Notes:  immunostaining  and  hepatic  L-CTGF  expressions  were  determined  as 
outlined in Table 2. Using sAs statistical software, Kendall tau (τ) rank correlation 
coefficients (middle column) were determined for the intensities of L-CTGF and 
blood tests performed at the time of liver transplantation (left-hand column).
Abbreviations: AsT, aspartate aminotransferase; ALT, alanine aminotransferase; 
ALP,  alkaline  phosphatase;  GGT,  gamma-glutamyltransferase;  L-CTGF,  lobular 
connective tissue growth factor; WBC, white blood cell count.Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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with hematological parameters than P-CTGF; 2) an inverse 
  relationship exists between WBC, PT, INR, and platelet count 
with L-CTGF expression in advanced BA; and 3) combina-
tion of dependent variables did not correlate with hepatic 
L-CTGF or P-CTGF expression. Interestingly, of all the 
dependent variables, WBC was noted to be most (inversely) 
corelated with L-CTGF-expression. This observation is 
important, given that WBC count is frequently depressed 
due to portal hypertension and splenomegaly in the setting 
of advanced cirrhosis in patients with BA. Apart from the 
inverse relationship between WBC and L-CTGF, most of the 
correctional coefficients were nonsignificant, suggesting that, 
even if CTGF plays a role in fibrogenesis, its expression does 
not correlate with characteristic hematological and biochemic 
abnormalities encountered in cirrhosis due to BA. This is not 
surprising in that although CTGF has been well-documented 
to be overexpressed in a variety of liver pathologies,12,33,34 spe-
cific mechanisms of CTGF overexpression remain obscure; 
thereby, its diagnostic or prognostic applications remain 
limited at the moment. Furthermore, apart from its fibrogenic 
potential, CTGF has an overarching biologic significance as 
a regulator of multiple cellular functions such as cell adhe-
sion, mitogenesis, chemotaxis, proliferation, differentiation, 
  neovascularization, apoptosis, and cell survival.35   Therefore, 
despite the compelling reasons to identify and validate novel 
biomarkers of HF, it appears quite reasonable to pause and 
ask: has the promise of CTGF to serve as a biomarker of 
HF been anticipated prematurely – without adequately 
elucidating underlying disease-specific mechanisms of its 
overexpression? Further data analyzing similar corelations 
from diverse liver diseases will help answer this question. 
However, in this study, one step proximal to its utilization 
as a biomarker of HF, hepatic CTGF expression is noted to 
be poorly correlated with routine blood tests and markers 
of progressive liver disease such as cholestasis, the cardinal 
feature of BA. However, several issues are quite important 
to recognize for the appropriate interpretation of the results 
presented in our study.
For example, due to the relatively small sample size, 
the scope of this report is restricted to mainly establishing 
a practical framework for the investigation of novel hepatic 
fibrogenic markers and their potential clinical use as biomark-
ers of liver fibrosis. Given that BA is a relatively uncom-
mon disease, multicenter studies are needed to assess the 
reproducibility of this work with a larger sample size. Other 
pertinent caveats about this report include the uniform nature 
of advanced liver cirrhosis, and the absence of a comparative 
control group. Both issues have relevance to the presented 
results, and we recognize that these are best addressed by 
prospective multicenter collaborative studies. Therefore, 
rather than making conclusions against or in favor of CTGF 
as a biomarker of liver fibrosis, we suggest that this work is 
viewed as one step forward to framing pertinent questions and 
knowing how to answer these   questions. For example, imme-
diate questions emerging from this work include: does blood 
level of CTGF correlate with   hepatic-CTGF-expression; 
and, if so, can blood CTGF levels be used as a surrogate for 
liver fibrosis. Due to ethical restriction on repeated biop-
sies, further work using experimental BA is needed to best 
address these questions. We are using rotavirus-induced BA 
to determine the usefulness of CTGF as a biomarker of HF in 
BA which may eventually encourage prospective multicenter 
investigations.
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